Biotech Values

[winchem21]

Glad to see GENR bringing on board technical expertise in this area and significantly ramping up R&D expenditures during the fourth quarter to get things moving.

The "Acting Capacity" hints of a temporary arrangement, perhaps until the closing of a deal later this year.

While the IL9, MSI1436, and chloride channel IP have significant potential, all will require significant capital, time, and involve increased technical risk. The moves today appear to reflect these realities in light of available resources.

Funding gained from success with squalamine and AMD would result in GENR being in a position to retain a greater fraction of future revenues from success in any of these other areas.

Overall, today's developments appear to be positive for shareholders and provide evidence of management making necessary decisions to increase the value of the company.

wc21